To determine the safety/tolerability, and immunogenicity of an experimental vaccine given as intramuscular injections followed by electrostimulation in cancer patients.

Inclusion Criteria:

• Patients must have stages II, III, or IV breast, colorectal, ovaria, of non-small cell lung cancer
• Patients will either be disease free following primary therapy or have advanced disease with a durable response (>3 months) after standard therapy
• Tumor antigen HER-2 and/or CEA must be measurable in the blood or detected by Immunohistochemistry staining of the biopsies obtained from the primary tumor or metastasis

Exclusion Criteria:

• Patients with prior treatment with any HER-2 and/or CEA containing vaccine
• Patients who have significant cardiac disease
• Patients with autoimmune disorders
• Patients who are pregnant or lactating